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ETATE-OF-THE-ART PAPER1403Emerging Tools for Diagnosis and Risk Assessment in ACS Patientsenjamin M. Scirica
cute coronary syndrome (ACS) encompasses a broad and heterogeneous population that
hallenges the clinician at each step of treatment in terms of: 1) diagnosis; 2) appropriate risk
tratification; 3) therapeutic decision-making; and 4) monitoring response to therapy. This
aper by Scirica reviews many of the available tools to guide clinical decision-making, with a
oal of understanding their advantages and limitations. Several emerging tools that may
otentially improve clinical care are reviewed, such as novel biomarkers, electrocardiographic
echniques, and imaging modalities. The statistical and analytical techniques to evaluate these
merging tools are also discussed.CLINICAL RESEARCH NVASIVE AND INTERVENTIONAL CARDIOLOGY1416>24 H Delay to PCI Associated With Worse Outcomes in ACS Patientsaul Sorajja, Bernard J. Gersh, David A. Cox, Michael G. McLaughlin, Peter Zimetbaum,
ostantino Costantini, Thomas Stuckey, James E. Tcheng, Roxana Mehran, Alexandra J. Lansky,
indy L. Grines, Gregg W. Stone
hile some have advocated for an as-soon-as-possible strategy of angiography and
evascularization, others argue that delaying percutaneous coronary intervention (PCI) will
llow medical therapy to safely reduce the thrombus burden in patients with non–ST-
egment elevation acute coronary syndromes (NSTE-ACS). Sorajja and colleagues performed
post-hoc analysis of data from the ACUITY (Acute Catheterization and Urgent
ntervention Triage strategY) trial with subjects who underwent PCI within 72 h stratified
nto 3 cohorts based on the timing of PCI. Outcomes were similar for those who underwent
CI 8 h and 8 to 24 h after presentation, but the 30-day risk of death was doubled in
hose whose PCI occurred 24 h after presentation. These findings suggest that urgent
ngiography and triage to revascularization should be a priority in NSTE-ACS patients.
ditorial Comment: David Antoniucci, p. 1425(continued on page A-28)
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ENVASIVE AND INTERVENTIONAL CARDIOLOGY1427Serial MRIs Show High Frequency of Asymptomatic Cerebral Embolism With TAVIlexander Ghanem, Andreas Müller, Claas P. Nähle, Justine Kocurek, Nikos Werner, Christoph Hammerstingl,
ans H. Schild, Jörg O. Schwab, Fritz Mellert, Rolf Fimmers, Georg Nickenig, Daniel Thomas
hanem and colleagues investigated the frequency and clinical outcomes of peri-interventional
erebral embolism in patients undergoing transfemoral aortic valve implantation (TAVI).
erebral diffusion-weighted magnetic resonance imaging (MRI) was performed before, 2
ays after, and 3 months after TAVI along with clinical assessments based on the
ational Institutes of Health Stroke Scale. Thirty patients were enrolled; 22 completed
he imaging protocol. Three patients (10%) had new neurological findings after TAVI,
ut 2 had complete resolution. Seventy-two percent of the patients with complete
maging data had an average of 5 new cerebral lesions. The incidence of clinically silent
eri-interventional cerebral embolic lesions after TAVI is high.NVASIVE AND INTERVENTIONAL CARDIOLOGY
1433levated Glucose Increases the Risk of
Contrast-Induced Nephropathy in Nondiabetics Undergoing PCIoshua M. Stolker, Peter A. McCullough, Seshu Rao, Silvio E. Inzucchi, John A. Spertus,
homas M. Maddox, Frederick A. Masoudi, Lan Xiao, Mikhail Kosiborod
hile diabetes is a known risk factor for contrast-induced acute kidney injury (CI-AKI), it is
nknown if pre-procedural glucose levels (regardless of pre-existing diabetes) predict this risk.
tolker and colleagues evaluated over 6,000 patients with acute myocardial infarction (AMI)
ndergoing coronary angiography using a large database. The primary outcome was CI-AKI
efined as a 0.3 mg/dl absolute or 50% relative serum creatinine increase during 48 h
ost-procedure. There was a strong association between glucose and CI-AKI risk in patients
ithout diabetes, ranging from 8.2% for those with glucose 110 mg/dl to 24.3% for those
200 mg/dl, but this association was not found in those being treated for diabetes. These
ndings imply that hyperglycemic patients without known diabetes should be recognized as a
igh-risk group for CI-AKI.
ditorial Comment: Martin A. Alpert, Carl Carlino, p. 1441(continued on page A-29)
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iYPERTROPHIC CARDIOMYOPATHY
1444requency and Clinical Features of HCM
Associated With 3 Sarcomere Protein Mutationsrancesca Girolami, Carolyn Y. Ho, Christopher Semsarian, Massimo Baldi, Melissa L. Will, Katia Baldini,
rancesca Torricelli, Laura Yeates, Franco Cecchi, Michael J. Ackerman, Iacopo Olivotto
n patients with hypertrophic cardiomyopathy (HCM), double or compound sarcomere gene
utation may be associated with earlier disease onset and more severe outcome. Girolami and
olleagues studied almost 500 unrelated index HCM patients and screened them for
yofilament gene mutations by direct deoxyribonucleic acid sequencing of 8 genes. Four
0.8%) harbored 3 mutations, 1 had a history of resuscitated cardiac arrest, and 2 others had
ppropriate device therapy after insertion of an implantable cardioverter-defibrillator.
oreover, 3 out of 4 patients had a severe phenotype with progression to end-stage HCM by
he fourth decade. HCM caused by 3 sarcomere gene mutations is rare but may confer a
emarkably increased risk and suggests the need for comprehensive genetic testing.ditorial Comment: Ray E. Hershberger, p. 1454EDIATRIC CARDIOLOGY
1456cute Pharmacokinetic and Hemodynamic
Responses to Oral Sildenafil in Children With PAHhristian Apitz, Janette T. Reyes, Helen Holtby, Tilman Humpl, Andrew N. Redington
pitz and colleagues studied the hemodynamic and corresponding pharmacokinetic responses
o a single, oral dose of sildenafil in children with pulmonary arterial hypertension (PAH)
ndergoing invasive testing. Thirty-six subjects received both inhaled nitric oxide (NO) and
ildenafil during cardiac catheterization with general anesthesia. The average pulmonary
asodilating capability of oral sildenafil was lower than that of inhaled NO. However, only
8% of subjects had a detectable sildenafil level. In those with detectable sildenafil levels, the
all in pulmonary vascular resistance was greater with sildenafil than with NO. These findings
uggest that suboptimal absorption of oral sildenafil may interfere with its utility during
nvasive testing in children with PAH.(continued on page A-30)
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1463enetic Variants in Catecholamine Storage Vesicle Protein
Interact to Trigger Systemic HypertensionConcept
Hypertension
Stress BP
Response to c-FOS, YY1, SRY
Promoter variants A-296C, A-261T
:
Gene
↓
Mechanism
↓
Physiological trait
↓
Disease trait
M
ec
ha
ni
sm
Application to CHGB:
T
im
euixing Zhang, Fangwen Rao, Lei Wang, Brinda K. Rana, Sajalendu Ghosh, Manjula Mahata,
any M. Salem, Juan L. Rodriguez-Flores, Maple M. Fung, Jill Waalen, Bamidele Tayo, Laurent Taupenot,
ushil K. Mahata, Daniel T. O’Connor
hromogranin B (CHGB) seems to play a necessary role in the biogenesis of catecholamine
ecretory vesicles. Previously, Zhang and colleagues described genetic variation at the CHGB
ocus, and concluded that sex and CHGB variants interact to influence blood pressure. In this
aper, CHGB is further explored with the discovery of 2 polymorphisms in the promoter
egion that disrupt transcription factor binding and are linked to systemic hypertension.
unctional studies confirm that the variants differed substantially in transcriptional efficiency
uring luciferase reporter activity assays. Differential binding of a male sex-specific
ranscription factor may link the variants to the sexual dimorphism seen in blood pressure.PRE-CLINICAL RESEARCH RE-CLINICAL RESEARCH
1476denyl Cyclase Linked to LV Hypertrophy, Dilation,
Dysfunction, and Fibrosis in a Pressure-Overload Modelong Tang, N. Chin Lai, H. Kirk Hammond, David M. Roth, Yuan Yang, Tracy Guo, Mei Hua Gao
ang and colleagues have been studying cardiac-directed adenylyl cyclase (AC) expression as
treatment for attenuating left ventricular (LV) hypertrophy and dysfunction in
ardiomyopathy. For this study, the effect of AC6 deletion was analyzed using an AC6-
eleted mice (AC6-KO) line and control mice who underwent transaortic constriction (TAC)
o induce pressure overload. AC6-KO had preserved LV ejection fraction and reduced LV
nd-diastolic dimension, LV mass, and LV fibrosis compared to control mice. The
eleterious effects of LV pressure overload appear to be mediated through AC6.YEAR IN CARDIOLOGY SERIES EAR IN CARDIOLOGY SERIES1487The Year in Atherothrombosisavier Sanz, Pedro R. Moreno, Valentin Fuster
his review by Sanz and colleagues summarizes several of the more significant papers related
o atherothrombosis published in the last year. The relevant studies are presented in 4
ategories: epidemiology, mechanisms of disease, early detection and risk stratification, and
revention and treatment.
